India continues to carry one of the world’s highest Thalassemia burdens, with an estimated 1–1.5 lakh children living with Thalassemia and nearly 10,000–15,000 affected babies born every year.
AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $26.2 million for the first quarter of 2026, reflecting strong launches in the US and most recently the UKCompany achieves positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results